Answers are grounded in this paper and cite their sources.
The use of aldosterone antagonists in heart failure has changed the epidemiology of hyperkalemia, requiring updated treatment approaches.
Hyperkalaemia is well recognized as a medical emergency. However, with the publication of trials showing benefit with renin-aldosterone axis suppression in heart failure, the epidemiology of patients presenting with hyperkalaemia has changed. The reported incidence of rate of serious hyperkalaemia (>6.0 mEq/l of potassium) ranges from 6 to 12% in patients on spironolactone with congestive cardiac failure (CCF). A rational choice of therapy based on present evidence is different from the traditionally used algorithm, given our understanding of the physiology relevant to this patient group. This article discusses the changing face of hyperkalaemia and the present evidence and discusses options in treatment of hyperkalaemia.
No takes yet. Share an insight, caveat, or question.
Chapagain et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: